Zacks Research Downgrades Microbot Medical (NASDAQ:MBOT) to Hold

Microbot Medical (NASDAQ:MBOT) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Several other brokerages have also recently issued reports on MBOT. Loop Capital set a $4.00 target price on Microbot Medical in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Microbot Medical in a research report on Wednesday, July 8th. B. Riley Financial reiterated a “buy” rating and issued a $4.00 price objective (down from $5.00) on shares of Microbot Medical in a research note on Friday, August 14th. HC Wainwright reissued a “buy” rating on shares of Microbot Medical in a report on Wednesday. Finally, Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $6.38.

Microbot Medical Price Performance

NASDAQ MBOT opened at $1.50 on Thursday. The business’s fifty day moving average price is $1.78 and its 200-day moving average price is $2.05. The stock has a market capitalization of $100.75 million, a price-to-earnings ratio of -6.25 and a beta of 1.06. Microbot Medical has a 1-year low of $1.44 and a 1-year high of $4.67.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Equities research analysts anticipate that Microbot Medical will post -0.31 EPS for the current year.

Hedge Funds Weigh In On Microbot Medical

Several institutional investors and hedge funds have recently bought and sold shares of MBOT. CIBC Bancorp USA Inc. bought a new stake in Microbot Medical during the third quarter valued at about $4,435,000. DNB Asset Management AS raised its stake in shares of Microbot Medical by 178.1% in the fourth quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock worth $1,355,000 after buying an additional 433,869 shares during the period. Vanguard Group Inc. raised its stake in shares of Microbot Medical by 14.3% in the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after buying an additional 292,923 shares during the period. Geode Capital Management LLC raised its stake in shares of Microbot Medical by 54.4% in the fourth quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 268,609 shares during the period. Finally, 683 Capital Management LLC purchased a new position in shares of Microbot Medical during the 4th quarter valued at about $512,000. 16.30% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Microbot Medical

Here are the key news stories impacting Microbot Medical this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating on Microbot Medical despite reducing several earnings forecasts, including its full-year 2027 estimate. The continued Buy recommendation provides some support for the stock by indicating the analyst still sees potential value in the company’s medical-device pipeline. MarketBeat Microbot Medical analyst estimates
• Neutral Sentiment: HC Wainwright now expects losses of approximately $0.08 per share in Q3 and Q4 2026, $0.08 in Q1 2027, and $0.07 in Q2 and Q3 2027. Its revised full-year forecasts call for a $0.29 loss in 2026 and a $0.28 loss in 2027, broadly consistent with the available consensus estimates. MarketBeat Microbot Medical earnings estimates
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods: Q3 2026 from a $0.06 loss to a $0.08 loss, Q4 2026 from $0.06 to $0.08, and full-year 2026 from a $0.24 loss to a $0.29 loss. The firm also reduced its 2027 forecast from a $0.25 loss to a $0.28 loss, signaling expectations for weaker near-term profitability.
• Negative Sentiment: Zacks Research downgraded MBOT from “Strong Buy” to “Hold.” The rating reduction is a negative sentiment signal and may weigh on investor demand, particularly because Microbot Medical remains unprofitable and has a market capitalization of roughly $101 million. Zacks Research

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.